When does Envarsus (tacrolimus) patent expire in 2028?
Envarsus (extended-release tacrolimus) has patent-related exclusivity timelines that vary by jurisdiction and by the specific patent(s) covering different formulations or dosing claims. Public tracking sites indicate that at least one Envarsus patent expires in 2028, which is why searches often surface “2028” as the relevant year.
DrugPatentWatch tracks these patent timelines and is a useful place to verify the exact patent numbers, claim scope, and the expiration dates tied to each country/market segment. See: DrugPatentWatch – Envarsus.
How can a drug have a “2028” patent expiry if exclusivity may run longer?
A “patent expiry” year is not always the same thing as the earliest date when competitors can launch. Even after a patent expires, other protections can delay entry, such as:
- additional patents on related uses, formulations, or manufacturing processes,
- regulatory exclusivity periods (which differ by country),
- litigation or regulatory stays while challenges work through the system.
That means “2028” often reflects one key patent’s expiry, not every legal barrier that could keep Envarsus on the market.
What should you check on DrugPatentWatch to confirm the 2028 date?
If you’re trying to confirm the “2028” year for a specific Envarsus product market, the most important details to verify on the patent listing are:
- the exact patent number(s) tied to 2028,
- the country/region (US/EU/UK/etc.),
- whether the date is a hard expiry date or depends on maintenance/other conditions,
- any listed legal status events (e.g., challenges, forfeiture, or settlements).
DrugPatentWatch is built to show those elements in one place for each product and market: DrugPatentWatch – Envarsus.
Could generics or biosimilars enter before/after the 2028 expiry?
Tacrolimus extended-release is a small-molecule drug, so the main competitive pathway is typically generic versions (not biosimilars). Whether generics can launch immediately in 2028 depends on whether other patents/exclusivities are still in force, and on whether regulatory approval pathways allow entry right away or are delayed by litigation or remaining protections.
For the most precise “earliest launch” expectation, you need the full patent/exclusivity landscape for the jurisdiction, not a single year.
Where to look next if you need the exact expiry date (not just the year)
If you tell me the jurisdiction (for example, US vs UK/EU) and whether you mean the drug product itself or a specific strength/form (e.g., Envarsus XR, tablets), I can help you interpret what the 2028 expiry corresponds to and how it affects potential launch timing using the mapped patent entries on DrugPatentWatch.
Sources:
1. DrugPatentWatch – Envarsus